Presentacion tardía de síndrome hemolítico-urémico atípico de novo en receptor de trasplante reno-pancreático resuelto con eculizumab

Nefrologia

Volumn 36, Issue 3, 2016, Pages 328-329

  Juega Mariño, Francisco Javier ^a   Sala, Neus ^a   López, Dolores ^a   Cañas, Laura ^a   Bonet, Josep ^a   Lauzurica, Ricardo ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; CREATININE; ECULIZUMAB; FIBRINOGEN; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MEMBRANE COFACTOR PROTEIN; MEROPENEM; MYCOPHENOLATE MOFETIL; PREDNISONE; TACROLIMUS; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ANTIBIOTIC AGENT;

ADULT; ANEMIA; ANTIBIOTIC THERAPY; CASE REPORT; CLINICAL FEATURE; COMPLEMENT ALTERNATIVE PATHWAY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FACTOR 1 GENE; FACTOR H GENE; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT REJECTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY PANCREAS TRANSPLANTATION; KLEBSIELLA; LATE ONSET DISORDER; LETTER; MAINTENANCE THERAPY; MCP GENES; MIDDLE AGED; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; URINARY TRACT INFECTION; ABDOMINAL PAIN; BLEEDING; CLINICAL ARTICLE; DIALYSIS; DIARRHEA; END STAGE RENAL DISEASE; FEVER; FIBROSING ALVEOLITIS; FOLLOW UP; GENERAL CONDITION DETERIORATION; GENETIC RISK; HAPLOTYPE; HOSPITAL DISCHARGE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT; LACTATE DEHYDROGENASE BLOOD LEVEL; ORGAN DONOR; PANCREAS TRANSPLANTATION; PLASMA EXCHANGE; SIGNAL TRANSDUCTION; VOMITING;

EID: 84979067029     PISSN: None     EISSN: 20132514     Source Type: Journal    
DOI: 10.1016/j.nefro.2016.02.003     Document Type: Letter

References (10)

1. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
2. Benz K., Amann K. Thrombotic microangiography: new insights. Curr Opin Nephrol Hypertens 2010, 19:242-247.
3. Caprioli J., Noris M., Brioshi S., Pianetti G., Castelletti F., Bettinaglio P., et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-1279.
4. Loirat C., Garnier A., Sellier-Leclerc A.L., Kwon T. Plasmatherapy in atypical hemolytic-uremic syndrome. Semin Thromb Hemost 2010, 36:673-681.
5. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
6. Campistol J.M., Arias M., Ariceta G., Blasco M., Espinosa M., Grinyó J.M., et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2013, 33:27-45.
7. Chandran S., Baxter-Lowe L., Olson J.L., Tomlanovich S.J., Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation - a case report. Transplant Proc 2011, 43:2097-2101.
8. Wilson C.H., Brown A.L., White S.A., Goodship T.H., Sheerin N.S., Manas D.M. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011, 92:e42-e43.
9. Satoskar A.A., Pelletier R., Adams P., Nadasdy G.M., Brodsky S., Pesavento T., et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 2010, 10:1804.
10. Le Quintrec M., Zuber J., Moulin B., Kamar N., Jablonski M., Lionet A., et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013, 13:663-675.